Organization (Industry)
INCYTE CORP
ClinicalTrials.gov lists INCYTE CORP as lead sponsor of 308 trials, counting the companies grouped under it. INCYTE CORP itself has 806 active development programs and 86 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 37 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 39 in 2026 and about 41 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 1 trial is registered to start in 2027 or later.
Logo Incyte, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers INCYTE CORP and 6 companies grouped under it: 308 lead-sponsored trials (288 its own, 20 in the grouped companies) and 2 legal-entity registrations (2 its own, 0 in the grouped companies).
Companies grouped under this page (6)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Incyte Biosciences International Sàrl | 10 | 0 |
| Incyte Biosciences Japan GK | 6 | 0 |
| Incyte BioSciences France | 1 | 0 |
| Incyte Biosciences Benelux | 1 | 0 |
| Incyte Biosciences Italy S.r.l | 1 | 0 |
Showing 5 of 6 member companies.
Disease areas (172)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Lymphoma | 55 |
| Lymphoma, Non-Hodgkin | 46 |
| Lung Neoplasms | 37 |
| Primary Myelofibrosis | 37 |
| Graft vs Host Disease | 29 |
Showing 5 of 172 disease areas.
Trials by start year as sponsor or collaborator (22)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 37 |
| 2025 | 44 |
| 2024 | 31 |
| 2023 | 40 |
| 2022 | 35 |
| 2021 | 33 |
| 2020 | 30 |
| 2019 | 32 |
| 2018 | 38 |
| 2017 | 32 |
Showing 10 of 22 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 38 trials still running at the 2026-10-09 snapshot; registered median of 21 months across 217 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (806)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Tafasitamab | Lymphoma | Phase 3 | 7 |
| Tafasitamab | Lymphoma, Non-Hodgkin | Phase 3 | 7 |
| Tafasitamab | Lymphoma, B-Cell | Phase 3 | 6 |
| LENALIDOMIDE | Lymphoma | Phase 3 | 4 |
| INCA034176 | Bronchiolitis | Phase 3 | 4 |
Showing 5 of 806 active programs.
Approved assets (86)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Ruxolitinib Cream | 32 |
| Ruxolitinib | 43 |
| Retifanlimab | 20 |
| PEMBROLIZUMAB | 15 |
| Pemigatinib | 15 |
Showing 5 of 86 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 43% hit target (n=174) | 44% on time (n=162) |
Journals published in (104)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Blood | 20 |
| The New England journal of medicine | 12 |
| Dermatology and therapy | 11 |
| Haematologica | 11 |
| Clinical lymphoma, myeloma & leukemia | 10 |
Showing 5 of 104 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 1,421 | 228 | 2025-12-16 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 5,141,242,000 | 1,286,650,000 | 2,050,152,000 |
| 2024 | 4,241,217,000 | 32,615,000 | 2,606,848,000 |
| 2023 | 3,695,649,000 | 597,599,000 | 1,627,594,000 |
| 2022 | 3,394,635,000 | 340,660,000 | 1,585,936,000 |
| 2021 | 2,986,267,000 | 948,581,000 | 1,458,179,000 |
| 2020 | 2,666,702,000 | -295,697,000 | 2,215,942,000 |
| 2019 | 2,158,759,000 | 446,906,000 | 1,154,111,000 |
| 2018 | 1,881,883,000 | 109,493,000 | 1,197,957,000 |
| 2017 | 1,536,216,000 | -313,142,000 | 1,326,134,000 |
| 2016 | 1,105,719,000 | 104,222,000 | 581,861,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (9)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-05-11 | Royalty / licensing | not disclosed | Sec extracted |
| 2025-02-10 | Follow-on offering | 2,257,874,848 | Edgar offerings |
| 2024-06-28 | Debt financing | not disclosed | Sec extracted |
| 2024-05-13 | Other financing | not disclosed | Sec extracted |
| 2022-02-08 | Other financing | not disclosed | Edgar offerings |
Showing 5 of 9 events.
FDA untitled letters (2)
Shown in this order: most recent issue date first.
| Issue date | Letter |
|---|---|
| 2026-04-22 | 192125 |
| 2025-09-09 | 188903 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 9 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 1 | 2011-07-27 |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | 51.2% | not disclosed |
Organization relationships (113)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 17 |
| M.D. Anderson Cancer Center | Co sponsors trial with | 8 |
| Merck & Co., Inc., Rahway, NJ, USA (United States) | Co sponsors trial with | 8 |
| Oregon Health & Science University | Co sponsors trial with | 8 |
| Moffitt Cancer Center | Co sponsors trial with | 7 |
Showing 5 of 113 relationships.
Latest dated events (1,898)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 1,898 events.
Biomarker capability evidence (1,880)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABL1 | Trial collaborator | Named in trial inclusion criteria |
| ABL1 | Trial collaborator | Named in trial inclusion criteria |
| ABL1 | Trial collaborator | Named in trial inclusion criteria |
| ABL1 | Trial sponsor | Named in trial inclusion criteria |
| ABL1 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 1,880 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, fda warning letters, fda recalls, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.